Immunic News

Immunic | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Nash Duane

Dec 9 08:31 ET

Immunic | 4: Statement of changes in beneficial ownership of securities-Officer Vitt Daniel

Dec 6 17:35 ET

Immunic | 4: Statement of changes in beneficial ownership of securities-Officer Tardio Jason

Dec 6 17:35 ET

Immunic | 4: Statement of changes in beneficial ownership of securities-Officer Muehler Andreas

Dec 6 17:35 ET

Immunic | 4: Statement of changes in beneficial ownership of securities-Officer Nash Duane

Dec 6 17:35 ET

Immunic | 4: Statement of changes in beneficial ownership of securities-Officer Whaley Glenn

Dec 6 17:35 ET

Immunic | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Avidity Partners Management LP(9.9%),Avidity Partners Management (GP) LLC(9.9%), etc.

Nov 14 17:37 ET

Immunic | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Janus Henderson Group plc(5.7%),Janus Henderson Biotech Innovation Master Fund Ltd(5.2%)

Nov 14 12:37 ET

Immunic | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-RTW Investments, LP(6.1%),Roderick Wong, M.D.(6.1%)

Nov 14 07:02 ET

Immunic | 4: Statement of changes in beneficial ownership of securities-Director Rudick Richard Alan

Nov 13 14:17 ET

Immunic | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(5.21%)

Nov 12 15:54 ET

Immunic | SC 13G: Statement of acquisition of beneficial ownership by individuals-Adage Capital Management, L.P.(6.21%),Robert Atchinson(6.21%), etc.

Nov 12 09:41 ET

Immunic | 10-Q: Q3 2024 Earnings Report

Nov 7 07:08 ET

Immunic | 8-K: Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7 06:48 ET

Immunic | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(5.21%)

Nov 4 11:54 ET

Immunic | 8-K: Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Oct 22 06:48 ET

Immunic | 8-K: Immunic hosts multiple sclerosis research and development day

Sep 10 16:09 ET

Immunic | 8-K: Addendum No. Six to Employment Agreement

Sep 3 08:36 ET

Immunic | 10-Q: Q2 2024 Earnings Report

Aug 8 07:19 ET

Immunic | 8-K: Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8 06:49 ET